Skip To Main Content
Katelyn T. Byrne on Muck Rack

Katelyn T. Byrne

As seen in: ScienceDirect, PNAS, BMC Genomics, EurekAlert!, Science Magazine, BioRxiv, Cell Press, The Lancet, National Today, The Journal of Immunology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katelyn T.

Contact Katelyn T., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

New Clues Explain Why Immunotherapy Fails in Pancreatic Cancer

|
By Katelyn T. Byrne
| National Today
Got story updates? Submit your updates here. › An X-ray view into the complex immune landscape within a pancreatic tumor, revealing the key role of regulatory T cells in shutting down the body's anti-cancer defenses.Portland Today Immunotherapy has largely failed as a treatment for pancreatic cancer, and researchers have discovered a key reason why. Pancreatic tumors reprogram immune cells called regulatory T cells (Tregs) to overtake and shut down the immune cells capable of killing the tumor.
Open in Who Shared Issue with article?

Research Reveals Pancreatic Cancer's Immunotherapy Block

|
By Katelyn T. Byrne
| National Today
Got story updates? Submit your updates here. › Cutting-edge research reveals how pancreatic tumors manipulate the immune system, providing new hope for immunotherapy breakthroughs.San Diego Today Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer — and identified a promising strategy to overcome that resistance.
Open in Who Shared Issue with article?

Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment

|
By Vivien I. Maltez, Charu Arora, Kyle P. Gribbin, Breanna P. Caruso, Margaret E. Haerr, Rina Sor, Qiaoshi Lian, Katie E Blise, Shamilene Sivagnanam, Rosalie C. Sears, Lisa M. Coussens, Robert H Vonderheide, Ronald N Germain, Katelyn T. Byrne
| Cell Press Verified
Keywords regulatory T cell tumor microenvironment CD40 agonist interferon-γ reprogramming Get full text access Log in, subscribe or purchase for full access. References 1. de Visser, K.E. ∙ Joyce, J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth Cancer Cell. 2023; 41:374-403 2. Gill, A.L. ∙ Wang, P.H. ∙ Lee, J. ... PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors Sci. Immunol.
Open in Who Shared Issue with article?
See all 24 articles